News Archive
|
14 Sep. 2012 Biomay Extends GMP Manufacturing Authorization for Phase III and IV BiologicalsBiomay announces the successful extension of its manufacturing authorization for biologicals for all clinical phases and for market supply. The respective authorization and certificate of GMP compliance were granted recently to...[more] |
|
28 Jun. 2012 Biomay to present at the Rodman & Renshaw 14th Annual Global Healthcare ConferenceBiomay AG announced today that the company has been selected to present at the prestigious 14th Annual Global Healthcre Conference organized by the investment bank Rodman & Renshaw. The conference will take place at the...[more] |
|
28 Jun. 2012 Innovative Grass Pollen Allergy Vaccine Shows Efficacy in Phase IIA Trial (June 16, 2012)A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and...[more] |
|
3 Nov. 2011 Biomay Initiates Development of its Novel Ragweed and Japanese Cedar Allergy Vaccines – Project Granted and Awarded by ZITBiomay announces today that the company received 500.000 Euro funding supporting the development of its novel vaccine candidates against ragweed and Japanese cedar pollen allergy.[more] |
|
25 Oct. 2011 Biomay announces Initiation of First Phase II Trial with its Grass Pollen Allergy Vaccine BM32Biomay announces today that the company has initiated a first-in-patient phase II trial with its innovative recombinant grass pollen allergy vaccine BM32.[more] |
|
1 Oct. 2011 Biomay Appoints Clinical Advisory BoardBiomay announces the appointment of world leading allergy specialists to its Clinical Advisory Board (CAB).[more] |
|
20 Jan. 2011 Biomay Appoints Rainer Henning as Chief Executive OfficerBiomay announces the appointment of Dr. Rainer Henning as new Chief Executive Officer.[more] |
|
2 Nov. 2010 Development of Biomay´s BM32 vaccine for grass pollen allergy progressing according to planBiomay announces that the development programme of BM32 – a new vaccine for immunotherapy of grass pollen allergy – is progressing well and according to plan.[more] |
|
1 Feb. 2010 Boehringer Ingelheim RCV and Biomay Cooperate in GMP Manufacturing of Plasmid DNABoehringer Ingelheim RCV GmbH & Co KG, one of the global leaders in the production of biopharmaceuticals and Biomay, a new player in the field of contract manufacturing of GMP biopharmaceuticals at small scale, announced today...[more] |
|
20 Jan. 2010 New Aliquot Sizes and Prices of Research-grade Recombinant AllergensBiomay wishes to inform its customers about a few changes in the distribution of its research-grade recombinant allergens.[more] |